摘要:
A process for the preparation of biologically active somatotropin from inclusion bodies of a recombinant host cell containing an inactive form of said somatotropin protein comprises the steps of: (a) contacting the inclusion bodies with an aqueous alcohol solution at an alkaline pH to solubilize said protein; and (b) bringing the solubilized protein into contact with a mild oxidizing agent to refold and form intramolecular disulfide bonds between cysteine residues of said protein.
摘要:
A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 nullm.
摘要:
The present invention relates to a novel compound of formula (I) and pharmaceutically acceptable salts, hydrates and solvates thereof which is an irreversible HIV protease inhibitor; a process for the preparation thereof; and a pharmaceutical composition containing the compound as an active ingredient which is useful for treating or preventing diseases caused by HIV infection. ##STR1##
摘要:
The present invention relates to novel compounds of formula (I) which have inhibitory activity against human immunodeficiency virus ("HIV") protease, a process for the preparation thereof, and compositions for prevention or treatment of AIDS by HIV infection comprising the above compounds as active ingredients. ##STR1## wherein: R.sup.1 is an aromatic group, a nitrogen-containing aromatic group, C.sub.1-4 alkyl group optionally substituted with an aromatic group or a nitrogen-containing aromatic group, C.sub.1-4 alkoxy group optionally substituted with an aromatic group or a nitrogen-containing aromatic group; R.sup.2 is an amino acid residue or a C.sub.1-8 alkyl group substituted with a C.sub.1-4 alkylsulfonyl group; R.sup.3 is a C.sub.1-4 alkyl group optionally substituted with an aromatic group; R.sup.4 is hydrogen or a C.sub.1-4 alkyl group; R.sup.5 is an aromatic group, a C.sub.1-10 alkyl group or a C.sub.1-4 alkyl groups optionally substituted with an aromatic group; and n is 1 or 2.
摘要:
A composition for the transdermal administration of a drug, comprising: 0.05 to 50 wt % of the drug based on the total weight of the composition; 1 to 30 wt % of an absorption promoter consisting of a diethylene glycol ether and a sorbitan ester in a weight ratio ranging from 1:4 to 4:1, based on the total weight of the composition; and a pharmaceutically acceptable adhesive matrix.
摘要:
The present invention relates to a process for producing a thermoplastic resin having high impact strength and good surface gloss, which comprises graft copolymerizing at least a vinyl cyanide compound and at least an aromatic vinyl compound for a short period of less than about 3 hours in the presence of rubber latex having high gel content. The rubber latex can be a mixture of two or more rubber latices having different particle size. The graft copolymer has the characteristics such that the degree of the inner occlusion into the resin is decreased and the degree of surface grafting is increased. Thereby, the resulted thermoplastic resin has a very high impact strength and good surface gloss, and the processability is greatly improved. In addition, when the graft copolymer is polymerized the level of coagulum formation is greatly decreased.
摘要:
Novel cis-epoxide compounds of formula (I) are useful for treating or preventing diseases caused by HIV infection: ##STR1## wherein A, B, R.sub.1 to R.sub.4 and n have the same meanings as defined in the specification. The novel HIV protease inhibitor of the formula (I) has a specific structure to form a stable bonding with the enzyme active site, which entails a highly enhanced irreversible inhibition against HIV protease.
摘要:
The present invention relates to novel compounds of formula (I) which has inhibitory activities against human immunodeficiency virus ("HIV") protease, a process for the preparation thereof, and compositions for prevention or treatment of AIDS by HIV infection comprising the above compounds as active ingredients. ##STR1## wherein: R.sup.1 is an aromatic group, a nitrogen-containing aromatic group, C.sub.1-4 alkyl group optionally substituted with an aromatic group or a nitrogen-containing aromatic group, C.sub.1-4 alkoxy group optionally substituted with an aromatic group or a nitrogen-containing aromatic group; R.sup.2 is an amino acid residue or a C.sub.1-8 alkyl group substituted with a C.sub.1-4 alkylsulfonyl group; R.sup.3 is a C.sub.1-4 alkyl group optionally substituted with an aromatic group; R.sup.4 is hydrogen or a C.sub.1-2 alkyl group; R.sup.5 is a C.sub.1-10 alkyl group optionally substituted with an aromatic group; and n is 1 or 2.